Asarina Pharma AB (publ) Q1 2022 Report released
Peter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals of our phase IIa Tourette study, despite tail-end Covid-19 effects at our study sites. We firmly expect to continue to do so. The study remains fully funded. We remain confident of reporting topline results in Q1 2023.”FINANCIAL HIGHLIGHTS · Staff costs declined to 0.6 (1.9) MSEK due to the previously communicated reduction in working time for the Asarina team in Q3/2021 · External R&D costs amounted to 2.6 (4.0) MSEK, the majority related to